TG Therapeutics, Inc.
- Jurisdiction
United States - LEI
529900X21UKABN9NJ529 - ISIN
US88322Q1085 (TGTX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€22.68 33.3% overvalued - Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Read full profile
Fundamentals
- Net revenue
€329.57M - Gross margin
87.4% - EBIT
€51.02M - EBIT margin
15.5% - Net income
€33.39M - Net margin
10.1%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: August 4, 2025 (Q2 2025)